Capillary leak syndrome cost-effectiveness of therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 6: | Line 6: | ||
==Overview== | ==Overview== | ||
==Cost-effective therapy== | ==Cost-effective therapy== | ||
{| class="wikitable" | |||
!Treatment | |||
!Mechanism of Action | |||
|- | |||
| colspan="2" | | |||
=== '''Endothelial signal transduction''' === | |||
|- | |||
|'''[[Bevacizumab]]''' | |||
| | |||
* [[Bevacizumab]] costs in 2014 averaged around $9324 for a total duration of 8 weeks | |||
* The average price of the drug was $66.60 per 10 mg given at 5 mg given every 2 weeks <ref name="pmid26380601">{{cite journal| author=| title=Bevacizumab Wins Cost-Effectiveness Contest in First-Line Metastatic Colorectal Cancer. | journal=Am Health Drug Benefits | year= 2015 | volume= 8 | issue= Spec Issue | pages= 10-2 | pmid=26380601 | doi= | pmc=4570073 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26380601 }}</ref> | |||
<br /> | |||
|- | |||
|'''Epoprostenol''' | |||
| | |||
|- | |||
|'''[[Theophylline]] + [[Terbutaline]]''' | |||
| | |||
* [[Theophylline]] | |||
* [[Terbutaline]] | |||
|- | |||
| colspan="2" | | |||
=== '''Immune modulation''' === | |||
|- | |||
|'''Corticosteroids''' | |||
| | |||
|- | |||
|'''Infliximab''' | |||
| | |||
|- | |||
|'''IVIG''' | |||
| colspan="1" rowspan="1" | | |||
|- | |||
|'''Plasmapheresis''' | |||
| | |||
|} | |||
==References== | ==References== | ||
Revision as of 05:47, 8 August 2022
|
Capillary leak syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Capillary leak syndrome cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Capillary leak syndrome cost-effectiveness of therapy |
|
FDA on Capillary leak syndrome cost-effectiveness of therapy |
|
CDC on Capillary leak syndrome cost-effectiveness of therapy |
|
Capillary leak syndrome cost-effectiveness of therapy in the news |
|
Blogs on Capillary leak syndrome cost-effectiveness of therapy |
|
Risk calculators and risk factors for Capillary leak syndrome cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: M. Hassan, M.B.B.S
Overview
Cost-effective therapy
| Treatment | Mechanism of Action |
|---|---|
Endothelial signal transduction | |
| Bevacizumab |
|
| Epoprostenol | |
| Theophylline + Terbutaline | |
Immune modulation | |
| Corticosteroids | |
| Infliximab | |
| IVIG | |
| Plasmapheresis | |